Table 2.
Treatment-era and clinical characteristics by patient-index diagnostic group
| Diagnostic group | ART duration at diagnosis, years, median (IQR) | Viral load available, n (%) | WHO stage III/IV, n (% of documented) | DTG-based ART, % of documented |
|---|---|---|---|---|
| Opportunistic CNS infection | 0.2 (0-2.2) | 105 (51.0) | 66 (38.8) | 76.0 |
| HIV-attributed/organic CNS | 5.0 (0.8–9.7) | 113 (76.4) | 15 (11.8) | 82.0 |
| Major depressive disorder | 7.5 (3.5–10.9) | 119 (86.2) | 18 (14.0) | 85.7 |
| Bipolar spectrum disorder | 6.5 (3.0-10.7) | 33 (82.5) | 6 (17.6) | 79.5 |
| Anxiety / stress-related | 6.4 (0.9–9.1) | 14 (82.4) | 2 (12.5) | 50.0 |
| Dementia spectrum | 2.5 (0.1-9.0) | 9 (60.0) | 6 (46.2) | 72.7 |
| Psychosis spectrum | 2.6 (0.1–11.2) | 9 (75.0) | 4 (33.3) | 75.0 |
| Substance use disorder | 4.0 (2.8–5.4) | 3 (75.0) | 1 (25.0) | 100.0 |
ART antiretroviral therapy, DTG dolutegravir, WHO World Health Organization. ART duration was available for 99.5% of index patients. Kruskal-Wallis test for ART duration across groups: H = 125.56, p < 0.001. Other neurological/medical (n = 1) omitted